Abstract
In this study, we assessed whether the apolipoprotein B/apolipoprotein A1 ratio (ApoB/ApoA1) is related to metabolic syndrome (MS) and its components in an urban Chinese population. A total of 709 community residents were enrolled. Metabolic syndrome was defined according to the International Diabetes Federation definition in 2005. The high ApoB/ApoA1 group was defined as the gender-specific upper quartile of the ApoB/ApoA1 ratio. Insulin resistance (IR) was defined as the upper quartile of Homa-IR. The ApoB/ApoA1 ratio was significantly higher in subjects with MS, compared to those without (p < 0.05). After adjusting for age and gender, subjects with MS (odds ratio [OR] = 3.5) or IR (OR = 2.3) were more likely to be in the high ApoB/ApoA1 group. The ApoB/ApoA1 ratio increased significantly as the number of MS components increased (p < 0.05). Taken together, these data demonstrate that the ApoB/ApoA1 ratio is strongly associated with MS and its components in an urban Chinese population.
Similar content being viewed by others
References
Alberti, K.G., P. Zimmet, J. Shaw, and IDF Epidemiology Task Force Consensus Group. 2005. The metabolic syndrome—a new worldwide definition. Lancet 366: 1059–1062.
International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available from http://www.idf.org/webdata/docs/MetS _def_update2006.pdf
Elovson, J., J.E. Chatterton, G.T. Bell, V.N. Schumaker, M.A. Reuben, D.L. Puppione, J.R. Reeve, and N.L. Young. 1988. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. Journal of Lipid Research 29: 1461–1473.
Walldius, G., I. Jungner, A.H. Aastveit, I. Holme, C.D. Furberg, and A.D. Sniderman. 2004. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine 42: 1355–1363.
Walldius, G., and I. Jungner. 2006. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. Journal of Internal Medicine 259: 493–519.
Walldius, G., I. Jungner, I. Holme, A.H. Aastveit, W. Kolar, and E. Steiner. 2001. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358: 2026–2033.
Yusuf, S., S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, L. Lisheng, and INTERHEART Study Investigators. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937–952.
van der Steeg, W.A., S.M. Boekholdt, E.A. Stein, K. El-Harchaoui, E.S. Stroes, M.S. Sandhu, N.J. Wareham, J.W. Jukema, R. Luben, A.H. Zwinderman, J.J. Kastelein, and K.T. Khaw. 2007. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Annals of Internal Medicine 146: 640–648.
Dunder, K., L. Lind, B. Zethelius, L. Berglund, and H. Lithell. 2004. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein A1 ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). American Heart Journal 148: 596–601.
Meisinger, C., H. Loewel, W. Mraz, and W. Koenig. 2005. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. European Heart Journal 26: 271–278.
Sierra-Johnson, J., A. Romero-Corral, V.K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.L. Hellénius, and R.M. Fisher. 2007. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. European Heart Journal 28: 2637–2643.
Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
Relimpio, F., F. Losada, A. Pumar, M.A. Mangas, F. Morales, and R. Astorga. 2002. Relationships of apolipoprotein B(100) with the metabolic syndrome in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 57: 199–207.
Muntner, P., J. He, J. Chen, V. Fonseca, and P.K. Whelton. 2004. Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Annals of Epidemiology 14: 686–695.
Onat, A., G. Can, G. Hergenç, M. Yazici, A. Karabulut, and S. Albayrak. 2007. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. International Journal of Obesity 31: 1119–1125.
Wallenfeldt, K., L. Bokemark, J. Wikstrand, J. Hulthe, and B. Fagerberg. 2004. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 35: 2248–2252.
Lind, L., B. Vessby, and J. Sundström. 2006. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology 26: 406–410.
Sierra-Johnson, J., V.K. Somers, F.H. Kuniyoshi, C.A. Garza, W.L. Isley, A.S. Gami, and F. Lopez-Jimenez. 2006. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. American Journal of Cardiology 98: 1369–1373.
Zhao, W.H., J. Zhang, Y. You, Q.Q. Man, H. Li, C.R. Wang, Y. Zhai, Y. Li, S.G. Jin, and X.G. Yang. 2005. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Zhonghua Yu Fang Yi Xue Za Zhi. 39: 306–310 (In Chinese).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhong, L., Li, Q., Jiang, Y. et al. The ApoB/ApoA1 Ratio is Associated with Metabolic Syndrome and its Components in a Chinese Population. Inflammation 33, 353–358 (2010). https://doi.org/10.1007/s10753-010-9193-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-010-9193-4